An observational study of alemtuzumab following fingolimod for multiple sclerosis.
Willis M, Pearson O, Illes Z, Sejbaek T, Nielsen C, Duddy M, Petheram K, van Munster C, Killestein J, Malmeström C, Tallantyre E, Robertson N.
Willis M, et al.
Neurol Neuroimmunol Neuroinflamm. 2017 Jan 10;4(2):e320. doi: 10.1212/NXI.0000000000000320. eCollection 2017 Mar.
Neurol Neuroimmunol Neuroinflamm. 2017.
PMID: 28101520
Free PMC article.